Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H36N.Cl |
Molecular Weight | 325.96 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(C)C=C1
InChI
InChIKey=ZCTSINFCZHUVLI-UHFFFAOYSA-M
InChI=1S/C20H36N.ClH/c1-3-4-5-6-7-8-9-10-11-12-13-14-17-21-18-15-20(2)16-19-21;/h15-16,18-19H,3-14,17H2,1-2H3;1H/q+1;/p-1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Hyaluronic acid biosynthesis Sources: https://www.ncbi.nlm.nih.gov/pubmed/3339273 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Depo-Medrol Approved UseINDICATIONS AND USAGE
Musculoskeletal Conditions. As with other adrenal steroids, DEPO-MEDROL Sterile
Aqueous Suspension has been found useful in alleviating the pain and lameness
associated with acute localized arthritic conditions and generalized arthritic conditions.
It has been used successfully to treat rheumatoid arthritis, traumatic arthritis, osteoarthritis,
periostitis, tendinitis, synovitis, tenosynovitis, bursitis, and myositis of horses;
traumatic arthritis, osteoarthritis, and generalized arthritic conditions of dogs. Allergic Conditions. This preparation is especially beneficial in relieving pruritus
and inflammation of allergic dermatitis, acute moist dermatitis, dry eczema, urticaria,
bronchial asthma, pollen sensitivities and otitis externa in dogs; allergic dermatitis and
moist and dry eczema in cats.Overwhelming Infections with Severe Toxicity. In dogs and cats moribund from
overwhelmingly severe infections for which antibacterial therapy is available (eg, critical
pneumonia, pyometritis), DEPO-MEDROL may be lifesaving, acting to inhibit the
inflammatory reaction, which itself may be lethal; preventing vascular collapse and
preserving the integrity of the blood vessels; modifying the patient’s reaction to drugs;
and preventing or reducing the exudative reaction which often complicates certain infections.
As supportive therapy, it improves the general attitude of the animal being
treated. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21018239
Curator's Comment: In rabbits intravitreal injection was used https://www.ncbi.nlm.nih.gov/pubmed/8505218
Rats: determinations of the minimum lethal
doses of myristyl-y-picolinium chloride (Miripirium) were made intravenously,
intraperitoneally, subcutaneously, and by stomach
tube. A lO-mg./ml. solution in physiological saline
was used intravenously and intraperitoneally.
A 30-mg/ml solution was used subcutaneously
and orally. The approximate LDw's
of myristyl-7-picolinium chloride are 200 mg/Kg
subcutaneously, 7.5 mg/Kg intraperitoneally,
30 mg/Kg intravenously, and 250 mg/Kg by
stomach tube.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1393904
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
17671
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
SUB08991MIG
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
100000080665
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
3D6CWI0P23
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
2748-88-1
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
DTXSID2046834
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
36338
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
220-387-1
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
3D6CWI0P23
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
6585
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY | |||
|
C166671
Created by
admin on Sat Dec 16 16:52:29 GMT 2023 , Edited by admin on Sat Dec 16 16:52:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD